Moderna Counters GSK’s Legal Challenge in RSV Vaccine Patent Dispute

Moderna Inc. has filed counterclaims against GlaxoSmithKline (GSK) in Delaware federal court amid an ongoing legal battle over a vaccine for respiratory syncytial virus (RSV). The filings accuse GSK of neglecting to develop its own RSV vaccine and instead relying on legal avenues to challenge Moderna. Moderna alleges that GSK has manipulated the United States patent system in its litigation strategy. The case underscores the competitive and contentious nature of the pharmaceutical industry, particularly in the high-stakes field of vaccine development. For further details on the legal strategies employed by both companies, you can read more in the original article.